Somewhat Favorable News Coverage Somewhat Unlikely to Impact XBiotech (XBIT) Stock Price

Press coverage about XBiotech (NASDAQ:XBIT) has been trending somewhat positive on Monday, Accern Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. XBiotech earned a coverage optimism score of 0.02 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 47.0459920442796 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

XBiotech (XBIT) traded up $0.08 during mid-day trading on Monday, reaching $4.20. The company had a trading volume of 41,700 shares, compared to its average volume of 56,875. XBiotech has a 12 month low of $2.77 and a 12 month high of $20.18. The firm has a market cap of $146.36 and a PE ratio of -3.33.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact XBiotech (XBIT) Stock Price” was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at

XBiotech Company Profile

XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response.

Insider Buying and Selling by Quarter for XBiotech (NASDAQ:XBIT)

Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit